August 17, 2021
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Ms. Margaret Schwartz
Re: Aptevo Therapeutics Inc.
Registration Statement on Form S-3
File No. 333-258758
Dear Ms. Schwartz:
In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-3 (File No. 333-258758) of Aptevo Therapeutics Inc. (the “Registration Statement”). We respectfully request that the Registration Statement become effective as of 4:05 p.m., Eastern Time, on August 19, 2021 or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please confirm that event with our counsel, Goodwin Procter LLP, by calling Sean M. Donahue at (202) 538-3557.
Very truly yours,
Aptevo Therapeutics Inc.
By: /s/ Marvin L. White
Marvin L. White
President and Chief Executive Officer
SoYoung Kwon, Aptevo Therapeutics Inc.
2401 4th Ave. Suite 1050, Seattle, WA 98121 | t 206.838.0500 | f 206.838.0503 | aptevotherapeutics.com | 1